PAYO vs. HQY, MEDP, BILI, WPP, ETSY, LYFT, MARA, AMTM, QBTS, and WSC
Should you be buying Payoneer Global stock or one of its competitors? The main competitors of Payoneer Global include HealthEquity (HQY), Medpace (MEDP), Bilibili (BILI), WPP (WPP), Etsy (ETSY), Lyft (LYFT), MARA (MARA), Amentum (AMTM), D-Wave Quantum (QBTS), and WillScot Mobile Mini (WSC). These companies are all part of the "business services" industry.
Payoneer Global vs. Its Competitors
HealthEquity (NASDAQ:HQY) and Payoneer Global (NASDAQ:PAYO) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.
HealthEquity has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Payoneer Global has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.
Payoneer Global has lower revenue, but higher earnings than HealthEquity. Payoneer Global is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.
Payoneer Global has a net margin of 13.82% compared to HealthEquity's net margin of 8.41%. Payoneer Global's return on equity of 17.78% beat HealthEquity's return on equity.
99.6% of HealthEquity shares are held by institutional investors. Comparatively, 82.2% of Payoneer Global shares are held by institutional investors. 1.5% of HealthEquity shares are held by company insiders. Comparatively, 2.6% of Payoneer Global shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
HealthEquity received 487 more outperform votes than Payoneer Global when rated by MarketBeat users. However, 72.29% of users gave Payoneer Global an outperform vote while only 70.40% of users gave HealthEquity an outperform vote.
HealthEquity presently has a consensus target price of $118.09, indicating a potential upside of 12.94%. Payoneer Global has a consensus target price of $10.44, indicating a potential upside of 49.96%. Given Payoneer Global's higher probable upside, analysts clearly believe Payoneer Global is more favorable than HealthEquity.
In the previous week, HealthEquity had 18 more articles in the media than Payoneer Global. MarketBeat recorded 31 mentions for HealthEquity and 13 mentions for Payoneer Global. Payoneer Global's average media sentiment score of 0.80 beat HealthEquity's score of 0.57 indicating that Payoneer Global is being referred to more favorably in the news media.
Summary
HealthEquity beats Payoneer Global on 9 of the 17 factors compared between the two stocks.
Get Payoneer Global News Delivered to You Automatically
Sign up to receive the latest news and ratings for PAYO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PAYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Payoneer Global Competitors List
Related Companies and Tools
This page (NASDAQ:PAYO) was last updated on 6/12/2025 by MarketBeat.com Staff
